A novel two-step mild hyperthermia for advanced liposomal chemotherapy

Gabizon, 2003, Pharmacokinetics of pegylated liposomal doxorubicin — review of animal and human studies, Clin. Pharmacokinet., 42, 419, 10.2165/00003088-200342050-00002 Allen, 2004, Drug delivery systems: entering the mainstream, Science, 303, 1818, 10.1126/science.1095833 O'Brien, 2004, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer, Ann. Oncol., 15, 440, 10.1093/annonc/mdh097 Koning, 2007, Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery, Anticancer Agents Med. Chem., 7, 425, 10.2174/187152007781058613 Judson, 2001, Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL (R)/CAELYX (R)) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group, Eur. J. Cancer, 37, 870, 10.1016/S0959-8049(01)00050-8 Yuan, 1994, Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft, Cancer Res., 54, 3352 Maeda, 2000, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J. Control. Release, 65, 271, 10.1016/S0168-3659(99)00248-5 Jain, 2010, Delivering nanomedicine to solid tumors, Nat. Rev. Clin. Oncol., 7, 653, 10.1038/nrclinonc.2010.139 Harrington, 2001, Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes, Clin. Cancer Res., 7, 243 Jain, 2005, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy, Science, 307, 58, 10.1126/science.1104819 Brunstein, 2006, Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery, Br. J. Cancer, 95, 1663, 10.1038/sj.bjc.6603461 Jain, 2006, Lessons from phase III clinical trials on anti-VEGF therapy for cancer, Nat. Clin. Pract. Oncol., 3, 24, 10.1038/ncponc0403 Kong, 2000, Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size, Cancer Res., 60, 4440 Kong, 2001, Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature, Cancer Res., 61, 3027 Li, 2013, Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia, J. Control. Release, 167, 130, 10.1016/j.jconrel.2013.01.026 van der Zee, 2000, Deep hyperthermia, comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial, Lancet, 355, 1119, 10.1016/S0140-6736(00)02059-6 Issels, 2010, Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study, Lancet Oncol., 11, 561, 10.1016/S1470-2045(10)70071-1 Song, 1984, Effect of local hyperthermia on blood flow and microenvironment: a review, Cancer Res., 44, 4721s Krawczyk, 2011, Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition, Proc. Natl. Acad. Sci. U. S. A., 108, 9851, 10.1073/pnas.1101053108 Northfelt, 1998, Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial, J. Clin. Oncol., 16, 2445, 10.1200/JCO.1998.16.7.2445 Yatvin MB, 1978, Design of liposomes for enhanced local release of drugs by hyperthermia, Science, 202, 1290, 10.1126/science.364652 Koning, 2010, Thermosensitive liposomes for the delivery of cancer therapeutics, Ther. Deliv., 1, 707, 10.4155/tde.10.65 Li, 2010, Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia, J. Control. Release, 143, 274, 10.1016/j.jconrel.2010.01.006 Li, 2013, Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy, J. Control. Release, 168, 142, 10.1016/j.jconrel.2013.03.011 Dicheva, 2013, Cationic thermosensitive liposomes: a novel dual targeted heat-triggered drug delivery approach for endothelial and tumor cells, Nano Lett., 13, 2324, 10.1021/nl3014154 Manzoor, 2012, Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors, Cancer Res., 72, 5566, 10.1158/0008-5472.CAN-12-1683 Hossann, 2007, In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes, Biochim. Biophys. Acta, 1768, 2491, 10.1016/j.bbamem.2007.05.021 Banno, 2010, The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo, J. Pharm. Sci., 99, 2295, 10.1002/jps.21988 Tagami, 2011, Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin, J. Control. Release, 152, 303, 10.1016/j.jconrel.2011.02.009 Al-Jamal, 2012, Pharmacokinetics & tissue distribution of temperature-sensitive liposomal doxorubicin in tumor-bearing mice triggered with mild hyperthermia, Biomaterials, 33, 4608, 10.1016/j.biomaterials.2012.03.018 Rouser, 1970, Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots, Lipids, 5, 494, 10.1007/BF02531316 Roehm, 1991, An improved colorimetric assay for cell-proliferation and viability utilizing the tetrazolium salt XTT, J. Immunol. Methods, 142, 257, 10.1016/0022-1759(91)90114-U Brouckaert, 2004, Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics, Int. J. Cancer, 109, 442, 10.1002/ijc.11703 Seynhaeve, 2007, Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response, Cancer Res., 67, 9455, 10.1158/0008-5472.CAN-07-1599 Kong, 2000, Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release, Cancer Res., 60, 6950 Needham, 2000, A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model, Cancer Res., 60, 1197 Poon, 2009, Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer, Expert. Opin. Pharmacother., 10, 333, 10.1517/14656560802677874 Negussie, 2011, Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound, Int. J. Hyperthermia, 27, 140, 10.3109/02656736.2010.528140